BCL3 is an established oncogene in hematologic malignancies, having been originally identified at a recurring translocation site in patients with B-cell chronic lymphoma and subsequently identified to be elevated in patients with anaplastic large cell lymphoma. This evidence concerns the gene BCL3 and cancer.